MCO — Moody's
A strong credit-ratings and risk-data franchise would diversify my AI-focused portfolio. At $464, the return still doesn't clear the hurdle.
Moody's combines an entrenched debt-ratings franchise with nearly entirely recurring Analytics revenue. It introduces drivers different from memory prices and hyperscaler capex, but ratings are issuance-sensitive and data centers support some fees. October 11 independent underwriting values FY2031 Base around $732, or 9.1% annualized from the October 9 $464.23 close before dividends.
The Risk Map made something obvious about my portfolio: several businesses can be strong investments and still earn their profits from the same AI infrastructure spending cycle. I continue to like that thesis. Moody’s is interesting because credit ratings, risk information and institutional analytics have different underlying economic drivers—not because I suddenly want to run away from volatility.
Why I care about this one
The ratings side (MIS) is entrenched in capital markets. Credit opinions are embedded in institutional mandates, investor processes and regulated workflows. Moody’s Analytics (MA) sells data, research and risk products that become part of banks’, insurers’ and other institutions’ daily systems.
That is real pricing power and switching friction, but not an unassailable monopoly. S&P and Fitch are direct competitors, and KBRA and DBRS are meaningful in securitized credit. Issuer-pays conflicts, litigation, regulation and AI-driven analytics competition deserve attention.
Q2 2026 revenue was $2.185B, up 15% year-on-year. MIS was $1.260B, up 25%, while MA was $925M, up 4% reported but 8% organic constant-currency. MA ARR reached $3.661B, up 9%, with 99% of quarterly MA revenue recurring. Ratings looks spectacular when issuance is strong; that is precisely why I don’t project 25% annual MIS growth into 2031.
The company guided full-year adjusted EPS to $16.50–$17.00 (GAAP: $16.00–$16.50) and free cash flow to $2.7B–$2.9B. At the October 9, 2026 close of $464.23, that’s ~27.7x FY2026 adjusted EPS midpoint and around a 3.5% forward FCF yield using 174.5M Q2 diluted shares. FY2026 and Q2 figures are from the July 22 earnings release.
The business is Moody's Investors Service plus Moody's Analytics: Q2 ratings transaction revenue jumped 34% with issuance while 99% of MA revenue recurred and ARR grew 9%. The regulatory credibility and institutional workflow moat looks durable but competition in structured finance, issuer-pays conflicts and AI-driven commoditization deserve material discounts. Part of ratings issuance is tied to the same AI infrastructure financing I want to diversify.
Q2 2026 / FY2026 guide (before Oct. 21 Q3)
Primary sources: Q2 2026 release and FY2026 guidance ↗ · 2025 annual report ↗ · SEC NRSRO statistics ↗
A fresh MIS + MA five-year operating model (rather than a simple forward EPS multiple) estimates FY2031 adjusted EPS ~$27.11 and Base $732, implying ~9.1% annualized from the October 9 close. The primary research question is whether independent ratings and risk-data earnings justify diverting capital from a correlated AI-focused portfolio at a price that meets the return hurdle. Q3 earnings are due October 21.
MA organic ARR can sustain double-digit expansion with strong contract retention and higher value-per-customer; MIS grows through issuance cycles in private credit, infrastructure and securitization; adjusted margins and diluted share reduction support >$27 EPS in FY2031 without 32x terminal earnings.
Persistent low debt issuance, rating-fee competition, NRSRO regulation, reputational/litigation events, faster AI commoditization of Analytics, unsustainable buybacks or weak cash conversion lower long-run per-share value. Elevated issuance linked to AI infrastructure means the diversification benefit is not absolute.
What gets this into the portfolio
Independent MIS/MA operating model tied to July 2026 reported data. MCO fits as a different earnings driver versus AI-infrastructure holdings, not a guaranteed hedge. At $464.23 October 9 close, FY2031 Base ~$732 offers ~9.1% price CAGR before dividends, below 12% starter hurdle; do not allocate yet. Q3 earnings Oct 21.
Valuation & scenario math
At ~$464, I can underwrite a very good company but only about 9.1% annual price appreciation in my Base. That is below my 12% starter hurdle for an individual company.
With the same Base forecast, the calculated maximum entry prices are about $405 (12%), $353 (15%) and $308 (18%). They’re valuation thresholds, not orders. A large share-price fall alone doesn’t earn new capital; changed economics or a genuinely attractive opportunity does.
An eventual 2%–4% compounder allocation could fit if the independent returns justify it. The index funds already supply some Financials exposure, and the next dollar still has to beat adding to an existing holding or the index. I don’t need to buy Moody’s to make a risk map look balanced.
At the $464.23 October 9 close, MCO is ~27.7x the FY2026 adjusted EPS midpoint of $16.75 and ~28.6x GAAP guidance midpoint. The October 11 bottom-up FY2031 model projects Base ~$11.94B revenue, 55% adjusted operating margin, ~$4.50B adjusted earnings and ~166M diluted shares, supporting ~$27.11 EPS. A 27x exit yields ~$732, about 9.1% annualized before dividends; 12% requires an entry around $405.
“My current view” is the output of my dated valuation framework, not a magical buy instruction. A BUY still has to beat the expected return of what I already own and the index before it gets actual money.
FY2031 adjusted operating Base ~$732 / required 5.23-year annualized price returns; dividends excluded
| Band | Buy price | Model base center | Annualized return at entry |
|---|---|---|---|
| Starter | $405 | $732 | +12.0% |
| Normal | $353 | $732 | +15.0% |
| Aggressive | $308 | $732 | +18.0% |
The zone label uses the live quote when available; the model itself is anchored to the Oct 9, 2026 reference close at $464. Starter near $405 for 12%, Normal near $353 for 15%, Aggressive near $308 for 18%, using the FY2031 Base and October 9 dated $464.23 reference. These are modeled maximum entry levels, not automatic buy orders.
I model Moody's Ratings and Analytics separately from approximately $8.34B of forecast FY2026 revenue, apply scenario-specific adjusted operating margins and net-income conversion, then account for actual diluted shares before an explicit exit P/E. The Base earns around 9.1% annualized at the October 9 $464.23 reference—not enough to buy solely for diversification.
| Normalized cycle EPS | ~$27 |
| Terminal P/E | 27x |
| Checkpoint | Dec 31, 2031 |
| Implied base price | ~$732/share |
This is a normalized-cycle checkpoint, not me compounding peak economics forever.
| Case | What has to be true | Target range | Total return* | Annualized return* |
|---|---|---|---|---|
| Bear | ~$18.23 normalized EPS · 21x P/E. From FY2026E MA $3.89B / MIS $4.45B, five fiscal years at MA +5% and MIS +1%, 50% adjusted operating margin, 66% operating-profit-to-adjusted-net conversion and a flat 174.5M diluted share count. Ratings issuance weakens and the premium compresses. | $346–$419 center ~$383 | -17.5% | -3.6% |
| Base | ~$27 normalized EPS · 27x P/E. MA +9%, MIS +6% annual revenue growth for five fiscal years, FY2031 adjusted operating margin 55%, adjusted net conversion 68.5%, and −1% annual diluted share shrinkage; growing Analytics and disciplined ratings pricing support the business. | $678–$786 center ~$732 | +57.7% | +9.1% |
| Bull | ~$34 normalized EPS · 32x P/E. MA +12%, MIS +10% annual revenue growth, 56% adjusted operating margin, 71% conversion and −1.25% annual diluted share shrinkage; private markets, analytics attachment and durable funding activity outperform. | $1,021–$1,157 center ~$1,089 | +134.5% | +17.7% |
*The static returns use the dated reference price. The annualized figure on the live page also refreshes from the current quote. For shorter model horizons, annualizing can make the number look ridiculous, so I care about total return and the underlying milestones at least as much.
Capital allocation
Very good tollbooth, very good cash allocator. Not much drama here.
Moody's can fund analytics/data investment, make selective acquisitions and buy back stock from a capital-light core. The thing I keep watching is whether having so much cash from ratings eventually tempts management into paying too much for growth outside the franchise.
Stage-relative, not some objective rating-agency grade. The number is there to force the judgment into the open. See the rubric →
What management is actually doing with the cash
The ratings arm is capital-light and Analytics earns reinvestment in proprietary data, integrated risk workflows and selective products. But first-half 2026 repurchases (~$2.165B) and dividends ($365M) exceeded the $1.532B free cash flow generated. I want actual diluted-share shrinkage and sustainable returns on acquisitions, not unlimited premium-priced buybacks.
What earns another dollar from me
Moody’s is due to report Q3 2026 on October 21. I want to see whether MIS’s strong transaction volumes hold up without assuming issuance is permanently buoyant, whether MA ARR can accelerate through organic growth, whether margins remain robust, and whether buybacks reduce the actual diluted share count after cash costs and stock compensation.
June 30 net debt was about $5.45B and first-half buybacks plus dividends exceeded free cash flow. That’s manageable, but the cash discipline is not a detail to ignore.
What can break this
I start from estimated FY2026 MA revenue ~$3.89B and MIS revenue ~$4.45B, both informed by FY2025 actual revenue and Moody’s 2026 guidance. I then model revenue growth separately, apply the consolidated adjusted operating margin and a net-income conversion check, account for share dilution/buybacks and choose an explicit terminal P/E.
| FY2031 estimate | Bear | Base | Bull |
|---|---|---|---|
| MA revenue growth | 5% | 9% | 12% |
| MIS revenue growth | 1% | 6% | 10% |
| Total revenue | ~$9.64B | ~$11.94B | ~$14.02B |
| Adjusted operating margin | 50% | 55% | 56% |
| Diluted shares | 174.5M | 166.0M | 163.9M |
| Adjusted EPS | ~$18.23 | ~$27.11 | ~$34.02 |
| Terminal adjusted P/E | 21x | 27x | 32x |
| Per-share value | ~$383 | ~$732 | ~$1,089 |
| Price CAGR, October 9 to FY2031 end | −3.6% | +9.1% | +17.7% |
The scenario graphic shows a ±2-turn terminal P/E sensitivity band, not a confidence interval. I exclude dividends from the modeled price returns. My bottom-up model uses five fiscal growth periods but measures the investment return over ~5.23 calendar years to December 31, 2031.
Ready at the right price, not owned. I want a long-duration compounder that diversifies earnings away from AI infrastructure. Moody’s clears the business-quality test. At the current reference price, it hasn’t cleared the expected-return hurdle.
For the complete sourced operating model, scenario sensitivities, competition and regulatory discussion, the AI-correlation caveat and the reverse-priced entry levels, read the October 11, 2026 Moody’s Research Note.